BioNetwork Partnering Summit
Privo CEO, Dr. Manijeh Goldberg, is invited to speak at the BioNetwork Partnering Summit.
Related Posts
01Jan
Our Oral Cancer treatment receives MIT’s Innovation Award two years in a row.
The project was awarded over $300,000 in funding from MIT’s Deshpande Innovation Center in 2012 and 2013 to support the... read more
17Apr
Privo Technology’s CEO, Manijeh Goldberg, speaks at IDEASTREAM, MIT Deshpande Center Symposium.
Watch Dr. Goldberg's presentation below regarding localized treatment of cancers in a more safe and effective way and the positive... read more
17Nov
PRV111, in Development as the First Non-Surgical Therapy for Early-Stage Non-Invasive Oral Cancer and High-Grade Dysplasias, Meets Its Primary Efficacy Endpoint in Ongoing Phase 2/3 Trial
Key Highlights: 92% complete response (CR) rate: Eleven of twelve evaluable patients achieved a centrally confirmed pathologic CR following a... read more
02Dec
MIT Selects Privo Technologies To Showcase the Company’s Groundbreaking Cancer Therapy in Japan and Korea.
Privo Technologies (Privo), a Massachusetts-based company with roots in the Langer lab at MIT, has been selected to introduce its... read more
07Dec
Privo Technologies, Inc. To Attend Bio Partnering at JPM January 10 to January 14, 2022
Peabody, MA-- Privo Technologies, Inc. (“Privo”), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer,... read more
10Jan
Honored at the White House Privo Technologies receives the 2016 National Tibbetts Award
Privo Technologies is pleased to announce that the company has won the 2016 National Tibbetts award for outstanding contributions to... read more
19Aug
Privo Technologies Named Winner of AIM-HI Accelerator Fund’s Inaugural Women’s Venture Competition 2020
PEABODY, Mass., Sept. 24, 2020 -- Privo Technologies, Inc. ("Privo"), a biopharmaceutical company focused on breakthrough localized treatments for tough to treat mucosal... read more
27Aug
Privo Technologies, Inc. Announces Publication in Nature Communications
PEABODY, Mass., Aug. 24, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo"), a phase 3 clinical stage biopharmaceutical company that has designed... read more
07Dec
Privo Technologies, Inc. To Attend Biotech Showcase January 17 to January 19, 2022
Peabody, MA-- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer, Easy on... read more
14Oct
Privo Technologies Completes Phase 2 Run-In in PRV111 Oral Cancer Trial, Highlighting Potential to Spare Patients from Surgery
Privo Technologies, Inc. a leader in localized cancer therapies, today announced the completion of enrollment in Arm 1 of the... read more
- © UX Strategy & Digital Branding
